Oppenheimer & CO Inc Genmab A/S Transaction History

Oppenheimer & CO Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 03, 2021	SELL	$32.88 - $44.57 $521,378 - $706,746	-15,857 Closed	0 $0
Q1 2021 May 10, 2021	SELL	$30.92 - $44.4 $391,570 - $562,281	-12,664 Reduced 44.4%	15,857 $521,000
Q4 2020 Feb 11, 2021	BUY	$33.66 - $40.76 $352,386 - $426,716	10,469 Added 57.99%	28,521 $1.16 Million
Q3 2020 Nov 13, 2020	BUY	$33.07 - $38.68 $596,979 - $698,251	18,052 New	18,052 $661,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.